Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

about

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

Item

http://www.wikidata.org/entity/Q57146198

description

im Oktober 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

@en

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

@nl

type

Item

label

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

@en

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

@nl

prefLabel

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

@en

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

@nl

P1476

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

@en

P2093

Adi Diab

http://www.w3.org/2001/XMLSchema#string

Maria E Cabanillas

http://www.w3.org/2001/XMLSchema#string

Mimi I Hu

http://www.w3.org/2001/XMLSchema#string

Naifa L Busaidy

http://www.w3.org/2001/XMLSchema#string

Priyanka C Iyer

http://www.w3.org/2001/XMLSchema#string

Ramona Dadu

http://www.w3.org/2001/XMLSchema#string

Sonali Thosani

http://www.w3.org/2001/XMLSchema#string

Steven G Waguespack

http://www.w3.org/2001/XMLSchema#string

Sumit K Subudhi

http://www.w3.org/2001/XMLSchema#string

Victor R Lavis

http://www.w3.org/2001/XMLSchema#string

P2860

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1

Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association.

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.

P304

1243-1251

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/THY.2018.0116

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30132401

http://www.w3.org/2001/XMLSchema#string

P921

endocrinology

P932

6157359

http://www.w3.org/2001/XMLSchema#string